Island Pharmaceuticals Ltd

As of June 30, 2026, Island Pharmaceuticals Ltd carries a market capitalization of 112.45M, placing it among publicly traded companies globally. Its enterprise value stands at 99.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Island Pharmaceuticals Ltd's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2026, Island Pharmaceuticals Ltd has 295.92M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 363.41, and the price-to-book ratio stands at 8.36.

These figures are as of June 30, 2026. The EV/Sales ratio of 352.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 99.58M versus a market cap of 112.45M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Island Pharmaceuticals Ltd maintains a current ratio of 24.62, meaning it holds 24.6x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Island Pharmaceuticals Ltd's stock has declined approximately 18.99% over the past 52 weeks. The 50-day moving average sits at 0.41, while the 200-day moving average is 0.40.

Over the twelve months ended June 30, 2026, Island Pharmaceuticals Ltd generated 282,657.00 in revenue and converted that into -9.84M in net income, yielding earnings per share of -0.04. EBITDA reached -10.23M, while operating income came in at -10.33M.

These figures are as of June 30, 2026. Total book value stands at 13.46M, with working capital of 12.72M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of -3,656.31 and net profit margin of -3,482.66 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -9.88, meaning Island Pharmaceuticals Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Island Pharmaceuticals Ltd's most recent stock split took place on February 28, 2024 with a 13:14 split ratio.

As of June 30, 2026, Island Pharmaceuticals Ltd has an Altman Z-Score of 120.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.